MedTrace Logo

Effects of Antidepressant Therapy on Brain Dopamine Transporter Activity in People With Major Depression

NCT00655057 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2020-04-16

Study results available
· View outcomes & findings →

Summary

This study will examine changes in brain dopamine transporter activity before and after antidepressant therapy.

Conditions

Interventions

DRUG

S-citalopram

Participants will take 10 to 30 mg of s-citalopram daily for 12 weeks.

BEHAVIORAL

Cognitive behavioral therapy (CBT)

Participants will attend twice weekly CBT sessions for 2 weeks and then once weekly sessions for 10 weeks. Sessions will focus on modifying thoughts and behaviors that may contribute to depression.

PROCEDURE

TRODAT-1 single photon emission computed tomographic (SPECT) imaging

Participants' striatal dopamine transporter (DAT) levels will be measured using \[99mTc\]TRODAT-1 SPECT with magnetic resonance imaging (MRI) co-localization on two separate occasions. Participants with depression will undergo TRODAT-1 SPECT imaging immediately before and after 12 weeks of their assigned treatment. Healthy participants will undergo TRODAT-1 SPECT imaging at baseline and 12 weeks later.

Sponsors & Collaborators

Principal Investigators

  • Jay D. Amsterdam, MD · University of Pennsylvania

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-10-31
Primary Completion
2009-08-31
Completion
2009-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00655057 on ClinicalTrials.gov